- Home
- OPT vs OCS Comparison
OPT vs OCS Comparison
Compare OPT & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- OCS
- Stock Information
- Founded
- OPT 1984
- OCS 2003
- Country
- OPT Australia
- OCS Switzerland
- Employees
- OPT N/A
- OCS N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- OPT Health Care
- OCS Health Care
- Exchange
- OPT Nasdaq
- OCS Nasdaq
- Market Cap
- OPT 855.6M
- OCS 916.3M
- IPO Year
- OPT 2020
- OCS N/A
- Fundamental
- Price
- OPT $5.09
- OCS $21.41
- Analyst Decision
- OPT Strong Buy
- OCS Strong Buy
- Analyst Count
- OPT 1
- OCS 5
- Target Price
- OPT $12.00
- OCS $28.80
- AVG Volume (30 Days)
- OPT 40.1K
- OCS 64.5K
- Earning Date
- OPT 03-03-2025
- OCS 03-17-2025
- Dividend Yield
- OPT N/A
- OCS N/A
- EPS Growth
- OPT N/A
- OCS N/A
- EPS
- OPT N/A
- OCS N/A
- Revenue
- OPT $261,859.00
- OCS $1,027,571.00
- Revenue This Year
- OPT N/A
- OCS $7.98
- Revenue Next Year
- OPT $46,864.26
- OCS $853.39
- P/E Ratio
- OPT N/A
- OCS N/A
- Revenue Growth
- OPT N/A
- OCS N/A
- 52 Week Low
- OPT $1.79
- OCS $10.55
- 52 Week High
- OPT $6.30
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- OPT 53.99
- OCS 52.07
- Support Level
- OPT $4.77
- OCS $20.95
- Resistance Level
- OPT $5.46
- OCS $21.86
- Average True Range (ATR)
- OPT 0.32
- OCS 0.56
- MACD
- OPT -0.11
- OCS -0.26
- Stochastic Oscillator
- OPT 20.60
- OCS 56.18
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.